David Kirn, 4D Molecular Therapeutics CEO
January 10, 2023 12:49 PM ESTUpdated January 11, 07:57 AM
R&D
Cell/Gene Tx

4D Mol­e­c­u­lar paus­es en­roll­ment in Fab­ry tri­als af­ter kid­ney prob­lems in three pa­tients

Kyle LaHucik

Senior Reporter

4D Mol­e­c­u­lar Ther­a­peu­tics said it has stopped en­rolling pa­tients in its two clin­i­cal tri­als of a gene ther­a­py be­ing in­ves­ti­gat­ed for Fab­ry dis­ease.

The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times